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The Effect of Erythropoietin on Neurotrophic Factors in
N9 Murine Microglial Cells*
Aim: In this study, we investigated whether interferon gamma (IFNγ), lipopolysaccharides (LPS) and amyloid
beta (AMYβ), as toxic stimulator agents, and erythropoietin (EPO), as a neurotrophic agent, have an effect on
the production of the following neurotrophic factors in the N9 murine microglia cell line: neurotrophin 3
(NT3), neurotrophin 4 (NT4), and brain-derived neurotrophic factor (BDNF).
Materials and Methods: Microglial cells were incubated with 50 μg/ml AMYβ, or 1 μg/ml of LPS plus 100
U/ml recombinant murine IFNγ, and/or one of three different concentrations (0.1, 1.0, and 5.0 U/ml) of
recombinant mouse EPO for 24 h.
Results: EPO 0.1 U/ml dose significantly increased NT4 levels compared to EPO 5.0 U/ml dose (P < 0.05).
EPO, in all doses, and AMYβ significantly induced NT4 secretion in microglias, while BDNF and NT3 were not
changed by AMYβ or EPO. LPS + IFNγ alone did not change neurotrophic factor levels in any group. However,
EPO with LPS and IFNγ induced NT4 secretion, especially the 5.0 U/ml dose of EPO.
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Conclusions: NT4 secretion, which was markedly induced by exposure to both AMYβ and EPO in N9 murine
microglias, may be an important result for neuronal survival. These results suggest that inflammatory
mechanisms in microglia may also involve the neuroprotective response of these cells; this may be a promising
area of study of neurodegenerative processes.
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N9 Fare Mikroglial Hücrelerinde Nörotrofik Faktörler Üzerine
Eritropoetinin Etkisi
Amaç: Bu çalışmada N9 murin mikroglia hücre hattında toksik uyarıcı ajanlar olarak interferon gama (IFNγ),
lipopolisakkarid (LPS), amiloid beta (AMYβ) ve nörotrofik ajan olarak eritropoetin (EPO)’in nörotrofik
faktörler olan nörotrofin 3 (NT3), nörotrofin 4 (NT4) ve beyin kökenli nörotrofik faktör (BDNF) üretimi
üzerine etkisi olup olmadığını araştırdık.
Yöntem ve Gereç: Mikroglial hücreler 50 μg/ml AMYβ veya 1 μg/ml of LPS + 100 U/ml IFNγ ve/veya EPO’nun
üç ayrı konsantrasyonu (0.1, 1.0 ve 5.0 U/ml) ile 24 saat inkübe edildi.
Bulgular: EPO’nun 0.1 U/ml dozu, EPO 5.0 U/ml dozuna göre, NT4 düzeylerini daha anlamlı olarak
arttırmıştır (P < 0.05) EPO’nun her üç dozu ve AMYβ mikroglial NT4 sekresyonunu anlamlı olarak
indüklerken; BDNF ve NT3 düzeyleri AMYβ veya EPO ile değişmedi. LPS + IFNγ uygulaması tek başına
herhangibir grupta nörotrofik faktör düzeylerini değiştirmedi. Fakat, EPO ile birlikte LPS + IFNγ uygulaması,
NT4 salınımını, özellikle EPO’nun 5.0 U/ml dozunda arttırdı.
Received: August 20, 2007
Accepted: August 27, 2008

Sonuç: N9 murin mikroglia hücre hattında AMYβ veya EPO uygulanımının NT4 salınımını indüklemesi,
nöronal hayatta kalım için önemli bir sonuç olabilir. Bu bulgular, mikrogliada inflamatuar mekanizmaların bu
hücrelerin nöroprotektif cevabını da kapsayan; belki de nörodejeneratif olaylarla ilgili çalışmalara da ışık
tutacak bir alan olabileceği yönündedir.
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Introduction
A glia-mediated, inflammatory immune response is an
important component of the neuropathophysiology of
neurodegenerative diseases such as Alzheimer’s disease
(AD) and Parkinson’s disease (PD). Activated microglia
can mediate neuronal cell death and the repair processes
of central nervous system (CNS) injuries. Recent studies
suggest that the activation of microglia in response to
injury, illness, aging, or other causes begins a cascade of
events that can best be characterized as an inflammatory
process. This cascade is mediated at first by the
proinflammatory cytokine interleukin 1, which is
overexpressed by the activated microglia. Microglias
produce and release certain growth factors that are
essential for neuron survival, such as erythropoietin
(EPO) and interferon gamma (IFNγ) (1,2). Amyloid
deposition, inflammation and regenerative mechanisms
are also early pathogenic events in experimental models
(3,4).
Erythropoietin (EPO) was first characterized as a
hematopoietic growth factor and has been in clinical use
for over a decade for the treatment of anemia. EPO is
currently named “NeoRecormon”, and since its receptor
was found in glial cells, it was assumed to have beneficial
effects on neuronal cells (5-7). The neuroprotective
effects of EPO have been demonstrated in vitro and in
vivo in a variety of CNS injury models, such as focal
cerebral ischemia and chemical–induced neurotoxicity (815). In CNS cell culture studies, EPO was shown to be
involved in the regulation of intracellular calcium and
signal mechanisms; the enhancement of calciumdependent or nondependent neurotransmitter release
may explain its neuroprotective efficacy. EPO has also
been proposed to be an antioxidant, anti-inflammatory
and trophic agent in the CNS due to its stimulation of
neuronal supportive cells and microglias and it increases
their viability (12-14,16). Another possibility is that EPO
combined with another cytokine such as IFNγ and
lipopolysaccharides (LPS) or various neuroactive drugs
stimulate glial cells maintaining support for neurons by
affecting neurotrophic factors and nitric oxide (NO)
production (8,9,15). In our previous studies, we
demonstrated that EPO increased antioxidant enzyme
activity and NO production in the substantia nigra in a
model of methyl-4-phenyl-1,2,3,6–tetrahydropyridine
(MPTP)-induced parkinsonism in C57BL mice (10,11).
Neurotrophic factors, such as nerve growth factor (NGF),
520
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neurotrophin 3 (NT3), neurotrophin 4 (NT4), and brainderived neurotrophic factor (BDNF), in addition to their
neurotrophic actions, may also regulate microglial
dynamics, thereby influencing the surrounding milieu
during neuronal inflammation and regeneration. In this
study, we investigated whether microglial activation with
IFNγ + LPS or amyloid beta (AMYβ) as toxic stimulator
agents, and with EPO as a neurotrophic agent, has an
effect on the production of neurotrophic factors (BDNF,
NT3 and NT4) in an N9 murine microglial cell line.

Materials and Methods
Microglial Cultures
The N9 murine microglia cell line was kindly provided
by Paola Ricciardi-Castagnoli (Cellular Pharmacology
Center, Milan, Italy) and maintained with Roswell Park
Memorial Institute (RPMI) medium supplemented with
5% fetal calf serum, 100 U/ml penicillin and 100 mg/ml
streptomycin. The purity of the microglia cultures was
assessed by immunostaining with monoclonal antibody
against CD11b/c (Invitrogen, Caltag Laboratories,
California, USA), and more than 90% of the cells were
positively stained.
Microglial cells were incubated with 50 mg/ml AMYβ
(Sigma-Aldrich, Taufkirchen, Germany), or 1 mg/ml LPS
(from Escherichia coli; Sigma-Aldrich, Taufkirchen,
Germany) plus 100 U/ml recombinant murine IFNγ
(Roche Diagnostics, Basel, Switzerland) and/or one of
three different concentrations (0.1, 1.0, and 5.0 U/ml) of
recombinant mouse EPO (Roche Diagnostics, Basel,
Switzerland) for 24 hours (h). None of the cytokines was
added to the control culture. In summary, the nine
treatment groups (three cell lines in each group) were as
follows:
1) Control
2) LPS (1 mg/ml) + IFNγ (100 U/ml)
3) AMYβ (50 mg/ml)
4) EPO (0.1 U/ml)
5) EPO (1.0 U/ml)
6) EPO (5.0 U/ml)
7) LPS (1 mg/ml) + IFNγ (100 U/ml) + EPO (0.1 U/ml)
8) LPS (1 mg/ml) + IFNγ (100 U/ml) + EPO (1.0 U/ml)
9) LPS (1 mg/ml) + IFNγ (100 U/ml) + EPO (5.0 U/ml)
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Results

After incubation for 24 h, BDNF, NT3 and NT4 levels
were duplicately measured by ELISA methods (Promega
Inc, Madison, WI, USA). Microplates were coated with
polyclonal antibodies specific to the neurotrophic factor
to be analyzed, which were diluted in carbonate coating
buffer (0.025 M sodium bicarbonate, 0.025 M sodium
carbonate, pH = 9.7) by incubating for 18 h at 4°C.
Nonspecific binding was prevented by adding a blocking
solution containing 1M phosphoric acid. The captured
antigens were bound by a second specific monoclonal
antibody (mAb). After washing, the amount of specifically
bound mAb was then detected using anti-rat IgG
conjugated to horse radish peroxidase as a tertiary
reactant. The unbound conjugate was removed and
following incubation with chromogenic substrate 3,3,5,5tetramethylbenzidine, the color change at 450 nm was
recorded, as this indicated the amount of neurotrophic
factors in each well.
Statistical Analysis
Comparisons were made using Mann-Whitney U test
and one-way analysis of variance (ANOVA), and Spearman
correlation coefficient by SPSS 10.0® (SPSS, Inc.,
Chicago, IL, USA). P values <0.05 were considered
statistically significant.

BDNF: AMYβ did not significantly change BDNF levels
compared to controls (P = 0.075). Similarly, EPO, LPS +
IFNc and LPS + IFNγ + EPO did not change BDNF levels a
significant amount (P > 0.05) (Table 1). A significant
positive correlation was found between BDNF and NT3 (P
< 0.0001; r = 0.667).
NT3: AMYβ did not significantly change NT3 levels
compared to the controls (P = 0.067). EPO, LPS + IFNC,
and LPS + IFNC + EPO did not change NT3 levels
significantly (P > 0.05) (Table 1).
NT4: The lowest NT4 levels were found in the control
group, while the highest levels were observed in the EPO
0.1 U/ml group. EPO at 0.1, 1.0 and 5.0 U/ml doses
increased NT4 levels significantly compared to controls (P
< 0.000 for all doses) and the levels of NT4 of the EPO
0.1 group were significantly higher than those of EPO
5.0 U/ml group (P < 0.05). AMYβ significantly increased
NT4 levels compared to the control group (P < 0.05 or
less for each group). Although levels of NT4 after LPS +
IFNγ treatment were not significantly different than that
of the controls, microglial activation by LPS + IFNγ + EPO
(0.1, 1.0 and 5.0 U/ml) significantly increased NT4 levels
compared to controls (P < 0.05, P < 0.05 and P <
0.0001, respectively). Of these groups, LPS + IFNγ +

Table 1. Levels of microglial brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT3)
and neurotrophin-4 (NT4) levels (pg/ml) after exposure to amyloid beta (AMYβ),
lipopolysaccharides (LPS) + interferon gamma (IFNγ), and erythropoietin (EPO). BDNF
and NT3 results are reported as mean ± SD while NT4 results are median.
Groups

BDNF

NT3

NT4

Control

3933 ± 388

1000 ± 98

501c

LPS + IFNγ

3583 ± 782

725 ± 240

504

AMYβ

4433 ± 759

1170 ± 166

1164d

EPO (0.1 U/ml)

3167 ± 580

952 ± 65

1859a,b

EPO (1.0 U/ml)

2817 ± 1327

1034 ± 192

1656 a

EPO (5.0 U/ml)

3583 ± 586

996 ± 51

1439

a
d

LPS + IFNγ + EPO (0.1 U/ml)

2817 ± 617

803 ± 82

1400

LPS + IFNγ + EPO (1.0 U/ml)

3383 ± 858

956 ± 172

1223d

LPS + IFNγ + EPO (5.0 U/ml)

3167 ± 231

1394 ± 537

1658

a,e

a

P < 0.0001, significantly higher than the control and LPS + IFN groups.
P < 0.05, significantly higher than the EPO 5.0 group.
c
P < 0.05, significantly lower than the other groups except LPS + IFNγ group.
d
P < 0.05, significantly higher than the control and LPS + IFNγ groups.
e
P < 0.01 significantly higher than the EPO 5.0 group.
b
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EPO 5.0 U/ml had a greater effect than the other only
EPO groups, and NT4 levels in the LPS + IFNγ + EPO 5.0
U/ml group were significantly higher than those of the
only EPO 5.0 U/ml group (P < 0.01) (Table 1).

Discussion
Neurotrophic factor expressions were investigated in
the pathogenesis of neurodegenerative diseases and were
found useful for both neuroactive drug screening in vitro
and possibly cell therapy for neurodegenerative diseases
(17,18). Cortical BDNF levels were upregulated, showing
an over 10-fold increase compared with age-matched
controls in AD. BDNF upregulation was significantly
correlated with the AMYβ load, and thus the authors
implicated this NT as playing an important role in the
regulation of neuronal survival, axonal regeneration
processes and neurological disorders, including epilepsy
(19-24). In PD, glia may upregulate NTs like BDNF, NT3,
NT4 and the tyrosine kinase receptors, TRKB and TRKC,
in response to signals released mainly from activated
microglial cells, failing nigral neurons and, to a lesser
extent, from reactive astrocytes (25). This glial response
may be the source of neurotrophic factors and can
protect against reactive oxygen species including NO and
glutamate (26). Alternatively, this glial response can also
cause release of deleterious pro-oxidant reactive species
and pro-inflammatory prostaglandins, LPS and IFNγ (25).
These are also powerful inducers of NGF and BDNF
production in mouse astrocyte cultures and thus play a
neuroprotective role in the CNS (27). Likewise, in brain
microglial cells, LPS modulate the expression of both NT3
and TRKC, which play pivotal roles in inflammatory and
degenerative disorders (15). Some studies indicated that
LPS induce microglial NGF expression and also analyzed
the effects of the inflammatory agent on TRKA, the highaffinity receptor for NGF (28,29). In particular, it was
reported that microglial NGF induces death of retinal
ganglion cells (30). Therefore, it remains to be
determined whether an induction in microglial NT
expression during inflammation is beneficial or
detrimental for neuronal or non-neuronal cells. Miwa et
al. (31) demonstrated that microglias express mRNAs of
BDNF and NT4 but not NT3 by LPS induction. Their
results for NT3 and NT4 are inconsistent with those of
Elkabes et al. (32), who showed that LPS induced
microglial NT3 expression, while BDNF and NT4
expression were unaltered by LPS.
522
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Proinflammatory cytokines were found to regulate
expression of EPO and EPO receptor in human neurons,
astrocytes, and microglia and further facilitate
interactions among different cell types in the human CNS
(18). Treatment with EPO inhibited the expression of
iNOS mRNA and nitrite production resulting from
proinflammatory stimulation by IFNγ and LPS in rat
oligodendrocytes (8). Park et al. (9) revealed that EPO
promoted neuronal cell differentiation through increased
release of NGF from astrocytes, and this effect may be
associated with signals of an extracellular signal-regulated
kinase pathway. Neuronal differentiation was even
further promoted when the neuronal stem cells were
cultured with an astrocyte culture medium treated with a
10 U/ml dose of EPO. Compared to untreated astrocytes,
EPO-treated astrocytes increased about two-fold in betaNGF, but did not raise BNDF and NT3 levels. Similar to
the study of Park et al., we also found in our study that
BDNF and NT3 levels were unchanged and positively
correlated with each other in microglias.
Wang et al. (33) showed that EPO treatment
significantly increased brain levels of BDNF, improved
functional recovery, and increased the density of cerebral
microvessels at the site of stroke. Zhang et al. (34) found
that EPO improved functional recovery after
experimental allergic encephalomyelitis in mice, possibly
via stimulating oligodendroglial BDNF expression. EPO
also affects the ability of oligodendrocytes to promote
myelin repair in the normal and damaged adult CNS.
It was reported by Viviani et al. (35) that exposure of
primary hippocampal neurons to EPO significantly
increased BDNF after 1 h. BDNF mRNA levels further
increased up to 4 h, to return to control levels after 18 h
of EPO treatment. Miwa et al. (15) found an increased
BDNF and NT4 mRNA expression in primary microglia
after LPS treatment for 12 h. Olivieri et al. (36) reported
increased BDNF and NT4 levels in SHSY5Y cell lines after
12-h AMYβ treatment. Mizuno et al. (37) found
decreased BDNF mRNA levels after 24 h incubation of
primary microglias with nicergoline. Elkabes et al. (32)
reported an increase in NT3 and NGF with LPS continuing
up to 24 h, while no change was noted in BDNF and NT4
levels. For the incubation period (24 h) selected in our
study, the studies of Mizuno (37) and Elkabes (32) were
taken as reference.
Both “EPO alone” groups and EPO + LPS + IFNγ
group activated microglia and significantly increased NT4
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levels compared to the control. However, the latter’s
significance was less than that of the former. We also
found that increases in NT4 were more evident at the 0.1
U/ml and 1.0 U/ml doses of EPO, which is similar to the
findings of Wen et al. (38). The enhanced NT4 secretion
in microglial cells after exposure to AMYβ may be an
inflammatory reaction against this toxic agent. That is,
microglias produce an immunological response to
inflammation caused by AMYβ, which is a molecule
responsible for neuronal injury in neurodegeneration.
EPO is more neuroprotective at lower doses and may also
be a useful agent for exploring the regulatory mechanism
of NT4 synthesis in murine microglias.
AMYβ is a toxic and EPO is a protective agent; both of
them significantly increased NT4 levels compared to the
control. Ending with similar results can be speculated to
arise by the following mechanisms: as a defense reaction
against AMYβ, microglial cells could have secreted
neurotrophic factor; on the other hand, neurotrophic
factor release could be the result of one of EPO’s
protective effects. Chong et al. (39) showed that EPO
treatment protected the primary hippocampal neurons
from apoptotic tissue injury in a rat model of AMYβ
toxicity. In their study, EPO in a concentration range of
0.001 ng/ml to 1000 ng/ml was not toxic to neurons. 150 ng/ml concentrations of EPO enhanced neuronal
survival. However, EPO concentration <1 ng/ml or >50
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ng/ml did have any positive effect on neuronal survival
during AMYβ administration. Chong et al. (39) showed
that in a concentration-specific manner, EPO was able to
protect DNA integrity and cellular membrane asymmetry
during AMYβ exposure. Additional studies in a number of
cell models also illustrate a tight therapeutic concentration
range for EPO (14,40-42). In the present study, AMYβ
significantly increased NT4 levels compared to controls.
Although it also caused increases in BDNF and NT3, these
were not significant. These results may indicate a reactive
inflammatory response against damage induced by AMYβ,
and having significant changes only in NT4 could be the
consequence of differing receptor sensitivities and receptor
densities of different glial cell types.
In summary, our study results reveal that both AMYβ
and EPO stimulate murine microglial cells, maintaining
support for neurons by increasing NT4 production, which
is known to facilitate neuronal survival. Targeting
microglias as mediators for neuroprotective drugs may be
a promising strategy in the treatment of
neurodegenerative processes.
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